Elevation Oncology, Inc. (ELEV)
NASDAQ: ELEV · Real-Time Price · USD
0.2601
+0.0034 (1.31%)
Mar 31, 2025, 10:51 AM EDT - Market open
Elevation Oncology Stock Forecast
ELEV's stock price has decreased by -95.05% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Elevation Oncology stock have an average target of 3.78, with a low estimate of 0.70 and a high estimate of 8.00. The average target predicts an increase of 1,353.29% from the current stock price of 0.26.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Elevation Oncology stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 4 | 5 | 5 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Buy → Hold Downgrades $5 | Buy → Hold | Downgrades | $5 | +1,822.34% | Mar 24, 2025 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $10 → $0.7 | Buy → Hold | Downgrades | $10 → $0.7 | +169.13% | Mar 21, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy → Hold Downgrades $7 | Buy → Hold | Downgrades | $7 | +2,591.27% | Mar 21, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $9 → $1 | Buy → Hold | Downgrades | $9 → $1 | +284.47% | Mar 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $1 | Strong Buy | Maintains | $6 → $1 | +284.47% | Mar 21, 2025 |
Financial Forecast
Revenue This Year
n/a
from 168.47M
Revenue Next Year
n/a
EPS This Year
-0.93
from -0.78
EPS Next Year
-0.99
from -0.93
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 44.8M | ||
| Avg | n/a | n/a | 12.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.86 | -0.61 | -0.60 | ||
| Avg | -0.93 | -0.99 | -1.04 | ||
| Low | -0.96 | -1.33 | -1.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.